StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
10
Publishing Date
2023 - 03 - 10
1
2023 - 02 - 10
1
2022 - 08 - 03
1
2022 - 07 - 27
1
2022 - 06 - 03
1
2022 - 04 - 12
1
2022 - 03 - 29
1
2022 - 02 - 01
1
2021 - 08 - 17
1
2021 - 04 - 22
1
Sector
Health technology
10
Manufacturing
1
Process industries
1
Tags
Abbvie
7
Active
10
Agreement
10
America
46
Antibiotics
7
Antibody
9
Application
9
Approval
10
Biotech
26
Cancer
54
Care
11
Collaboration
11
Covid
34
Covid-19
25
Device
11
Diabetes
7
Disease
39
Distribution
11
Drug
110
Drug delivery
12
Earnings
7
Ema
7
Europe
17
Expected
28
Fda
14
Food
22
Genetown
9
Global
159
Growing
34
Growth
192
Health
22
Hiv
12
Infection
10
Infections
9
Influenza
9
Iot
19
License
10
Liver
15
Market
447
Merge
11
N/a
793
Nutrition
12
People
16
Pharma
11
Pharmaceuticals
12
Positive
12
Reach
24
Report
140
Research
88
Respiratory
16
Results
19
Risk
8
Set
14
System
11
Technology
23
Therapeutics
84
Therapy
24
Treatment
98
Trial
13
Vaccine
56
Entities
Abbott laboratories
25
Abbvie inc.
37
Adc therapeutics sa
19
Adma biologics inc
17
Agios pharmaceuticals, inc.
11
Allied corp.
7
Alnylam pharmaceuticals, inc.
13
Alvotech lux holdings s.a.s.
7
Amgen inc.
22
Amneal pharmaceuticals, inc.
16
Amphastar pharmaceuticals, inc.
9
Ani pharmaceuticals, inc.
17
Argenx se
10
Arrival
14
Atlanticus holdings corporation
8
Aveo pharmaceuticals, inc.
20
Bausch health companies inc.
8
Beigene, ltd.
25
Biocryst pharmaceuticals, inc.
16
Biogen inc.
20
Blueprint medicines corporation
23
Boston scientific corporation
8
Bristol-myers squibb company
48
Calliditas therapeutics ab
8
Clovis oncology, inc.
19
Cns pharmaceuticals, inc.
11
Eli lilly and company
46
Epizyme, inc.
18
Exelixis, inc.
14
Franchise group, inc.
15
Gilead sciences, inc.
16
Glaxosmithkline plc
10
Guardant health, inc.
12
Halozyme therapeutics, inc.
9
I-mab
8
Illumina, inc.
12
Incyte corporation
41
Jaguar health, inc.
8
Jazz pharmaceuticals plc
8
Johnson & johnson
95
Kamada ltd.
11
Karyopharm therapeutics inc.
31
Lithium corp
11
Medtronic plc
28
Merck & company, inc.
8
Novartis ag
21
Novavax, inc.
10
Orange
21
Perrigo company
22
Pfizer, inc.
31
Reata pharmaceuticals, inc.
9
Regeneron pharmaceuticals, inc.
32
Rigel pharmaceuticals, inc.
11
Sanofi
98
Takeda pharmaceutical company limited
21
Teva pharmaceutical industries ltd
13
Verastem, inc.
10
Vertex pharmaceuticals incorporated
8
Viatris inc.
8
Y-mabs therapeutics, inc.
19
Symbols
ABBV
3
ACAD
1
ADCT
1
ALB
1
AMGN
1
ANAB
1
AZN
2
AZNCF
2
BIIB
1
BMY
1
CTIC
1
GLAXF
7
GSK
10
JNJ
2
LLY
2
NBIX
1
NPCE
1
NVS
3
NVSEF
3
PFE
3
SNY
3
SNYNF
3
TEVJF
3
Exchanges
Nasdaq
7
Nyse
10
Crawled Date
2023 - 03 - 10
1
2023 - 02 - 10
1
2022 - 08 - 03
1
2022 - 07 - 27
1
2022 - 06 - 03
1
2022 - 04 - 12
1
2022 - 03 - 29
1
2022 - 02 - 01
1
2021 - 08 - 17
1
2021 - 04 - 22
1
Crawled Time
04:00
1
06:00
1
08:00
1
14:30
1
17:00
1
18:00
1
20:00
1
21:00
2
23:00
1
Source
www.biospace.com
5
www.prnewswire.com
5
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Approval
entities :
Glaxosmithkline plc
save search
Diffuse large B-cell lymphoma (DLBCL) therapeutics market size to increase by USD 2,061.88 million between 2022 and 2027; Growth driven by increasing approval of therapeutics - Technavio
Published:
2023-03-10
(Crawled : 23:00)
- prnewswire.com
AMGN
|
News
|
$273.085
-0.17%
-0.17%
2.5M
|
Health Technology
|
Email alert
Add to watchlist
CTIC
|
$9.09
0.05%
11M
|
Health Technology
|
Email alert
Add to watchlist
GLAXF
|
News
|
$19.54
-14.18%
2.6K
|
Health Technology
|
Email alert
Add to watchlist
ABBV
|
News
|
$167.8
-1.03%
-0.06%
4.1M
|
Health Technology
|
Email alert
Add to watchlist
NVSEF
|
News
|
$96.0
6.88%
52K
|
Health Technology
|
Email alert
Add to watchlist
NVS
|
News
|
$98.35
1.1%
0.0%
2.2M
|
Health Technology
|
Email alert
Add to watchlist
TEVJF
|
News
|
$12.37
-24.22%
380
|
Health Technology
|
Email alert
Add to watchlist
GSK
|
News
|
$40.86
-0.92%
-0.15%
1.7M
|
Health Technology
|
Email alert
Add to watchlist
ADCT
|
$4.78
-3.82%
0.0%
280K
|
Health Technology
|
Email alert
Add to watchlist
approval
therapeutics
growth
market
US FDA grants regular approval for Jemperli for the treatment of patients with recurrent or advanced mismatch repair-deficient endometrial cancer
Published:
2023-02-10
(Crawled : 08:00)
- prnewswire.com
GLAXF
|
News
|
$19.54
-14.18%
2.6K
|
Health Technology
|
7.3%
|
O:
-2.43%
H:
0.66%
C:
0.66%
GSK
|
News
|
$40.86
-0.92%
-0.15%
1.7M
|
Health Technology
|
12.16%
|
O:
-1.07%
H:
0.06%
C:
-0.55%
ANAB
|
$19.25
0.37%
0.36%
390K
|
Health Technology
|
-25.74%
|
O:
0.04%
H:
1.27%
C:
-0.62%
treatment
fda
grants
approval
cancer
Neurologic Disorders Therapeutics Market Size to Grow by USD 33.46 billion, Approval Of Novel Drugs to Boost Market Growth - Technavio
Published:
2022-08-03
(Crawled : 04:00)
- prnewswire.com
GLAXF
|
News
|
$19.54
-14.18%
2.6K
|
Health Technology
|
-4.91%
|
O:
-1.8%
H:
0.2%
C:
0.0%
SNYNF
|
News
|
$94.25
-2.18%
480
|
Health Technology
|
-6.74%
|
O:
-2.6%
H:
0.0%
C:
-0.76%
NPCE
|
$13.525
-3.46%
-3.59%
44K
|
Manufacturing
|
135.01%
|
O:
0.52%
H:
3.71%
C:
-2.93%
NVS
|
News
|
$98.35
1.1%
0.0%
2.2M
|
Health Technology
|
15.62%
|
O:
0.11%
H:
0.31%
C:
-0.34%
GSK
|
News
|
$40.86
-0.92%
-0.15%
1.7M
|
Health Technology
|
-0.78%
|
O:
-0.29%
H:
0.24%
C:
-0.58%
ABBV
|
News
|
$167.8
-1.03%
-0.06%
4.1M
|
Health Technology
|
18.81%
|
O:
0.32%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
-4.28%
|
O:
-0.17%
H:
0.12%
C:
-1.29%
BIIB
|
$201.91
4.52%
4.32%
3.3M
|
Health Technology
|
-3.42%
|
O:
0.41%
H:
3.35%
C:
1.71%
ACAD
|
News
|
$16.57
-1.02%
-1.03%
1.3M
|
Health Technology
|
10.53%
|
O:
2.47%
H:
2.8%
C:
-2.67%
approval
therapeutics
growth
market
GSK Announces US FDA Approval of Benlysta (Belimumab) for Pediatric Patients With Active Lupus Nephritis
Published:
2022-07-27
(Crawled : 20:00)
- biospace.com/
GSK
|
News
|
$40.86
-0.92%
-0.15%
1.7M
|
Health Technology
|
-3.9%
|
O:
-0.56%
H:
3.36%
C:
2.98%
fda
active
lupus
approval
Global Panic Disorders Market Insights | Size | Shares | Trends | Growth | Industry Analysis [2020-2030] Panic disorders, also known as anxiety disorder deals with recurrent and unexpected panic attacks. PET-CT Scanner Devices Market: Competitive Landscape Analysis With Forecast by 2031 Wilmington, Delaware: According to the report, the global PET-CT scanner devices market was valued over US$ 200 Mn in 2020 and is projected to expand at a CAGR of ~3% from 2021 to 2031. Portal Hypertension Market Insights | Current Trends | Growth Opportunity | Global Industry Analysis [2020-2030] At present, treatment options for portal hypertension is limited due to the dearth of approval of specialized drugs. Spatial Genomics & Transcriptomics Market to Experience Significant Growth by 2027 Wilmington, Delaware: The spatial genomics & transcriptomics market is prognosticated to bring profitable growth during the assessment period of 2019-2027. Teleradiology Services Market to Make Great Impact in Near Future by 2031 Wilmington, Delaware: According to the report, the global teleradiology services market was valued over US$ 6.4 Bn in 2020. Anti-depressants Drugs and Therapies Market to Witness a Pronounce Growth by 2025 Wilmington, Delaware: Anti-depressants medications lower the symptoms of depression, dysthymia, chronic depression, and anxiety disorders. B-Cell Non-Hodgkin’s Lymphoma (NHL) Market to Offer Ample Growth Opportunities by 2027 Wilmington, Delaware: Non-Hodgkin’s lymphoma is a group of heterogeneous proliferative malignancies. Heightening Healthcare Spending Opening Growth Avenues for Collateral Ligament Stabilizer System Market, Reaching US$ 3.5 Billion in 2032: Fact.MR Study Fact.MR – A Market Research and Competitive Intelligence Provider: The global collateral ligament stabilizer system market is expected to reach US$ 3.5 Billion by the end of the 2022-2032 forecast period, growing at a CAGR of 6.1%, concludes a recently published report by Fact.MR. Breast Cancer Liquid Biopsy Market Trends, Growth, Analysis and Future Scope, 2026 Wilmington, Delaware: A biopsy is a tissue or cell sample taken from any part of the patient’s body and examined in the lab for the detection of cancer. Cerebral Palsy Market Size, Shares, Trends and Growth | Global Industry Analysis [2020-2030] The global cerebral palsy market is picking up steam due to increasing awareness about the condition amongst parents. Continuous Glucose Monitoring Market: Competitive Research and Precise Outlook 2021 to 2028 Wilmington, Delaware: The global continuous glucose monitoring market depicts the presence of a large competitive vendor landscape, says Transparency Market Research on the basis of a newly research report. Crow’s Feet Market Key Trends and Opportunity Analysis up to 2026 Albany NY, United States: The demand within the global crow’s feet market has been escalating on account of vital advancements in the field of dermatology in recent times. HIV Associated Lipodystrophy Syndrome Market Insights | Global Industry Analysis [2020-2030] HIV-associated lipodystrophy is a syndrome that are found in human immune-deficiency virus -infected patients who are being administered with active antiretroviral medications for the treatment of HIV infection. Global Mail Service Pharmacy Market | Size | Shares | Trends | Growth | Forecast [2020-2030]
Published:
2022-06-03
(Crawled : 06:00)
- biospace.com/
GLAXF
|
News
|
$19.54
-14.18%
2.6K
|
Health Technology
|
-25.62%
|
O:
-1.55%
H:
0.0%
C:
0.0%
SNYNF
|
News
|
$94.25
-2.18%
480
|
Health Technology
|
-11.94%
|
O:
-0.94%
H:
0.0%
C:
0.0%
AZNCF
|
News
|
$140.3
-4.19%
1.5K
|
Health Technology
|
5.15%
|
O:
-0.4%
H:
4.05%
C:
-1.35%
PFE
|
News
4
|
$26.27
-0.19%
-0.15%
23M
|
Health Technology
|
-49.77%
|
O:
0.57%
H:
0.0%
C:
0.0%
GSK
|
News
|
$40.86
-0.92%
-0.15%
1.7M
|
Health Technology
|
-5.48%
|
O:
-0.14%
H:
0.0%
C:
0.0%
LLY
|
News
|
$732.2
-1.81%
0.18%
2.1M
|
Health Technology
|
142.64%
|
O:
-2.25%
H:
0.0%
C:
0.0%
BMY
|
$48.86
-0.27%
-0.02%
16M
|
Health Technology
|
-35.26%
|
O:
-1.4%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
-11.57%
|
O:
-0.09%
H:
0.0%
C:
0.0%
NBIX
|
News
4
|
$138.91
-0.84%
-0.85%
880K
|
Health Technology
|
50.93%
|
O:
2.29%
H:
0.0%
C:
0.0%
AZN
|
News
|
$71.175
0.46%
0.46%
6.1M
|
Health Technology
|
7.08%
|
O:
-0.56%
H:
0.82%
C:
-0.64%
lipodystrophy
treatment
research
system
active
services
report
service
growing
hiv
profitable
hypertension
genomics
expected
virus
approval
cancer
growth
group
market
breast cancer
infections
Global Pharmaceutical API Manufacturing Market Report 2022-2030: Stringent Regulations for Approval of Pharmaceutical Drugs Restraining Growth
Published:
2022-04-12
(Crawled : 17:00)
- prnewswire.com
AZNCF
|
News
|
$140.3
-4.19%
1.5K
|
Health Technology
|
-1.88%
|
O:
-0.86%
H:
1.21%
C:
1.21%
NVSEF
|
News
|
$96.0
6.88%
52K
|
Health Technology
|
26.1%
|
O:
0.16%
H:
0.22%
C:
0.22%
NVS
|
News
|
$98.35
1.1%
0.0%
2.2M
|
Health Technology
|
4.91%
|
O:
-0.48%
H:
0.09%
C:
-0.68%
GSK
|
News
|
$40.86
-0.92%
-0.15%
1.7M
|
Health Technology
|
-12.97%
|
O:
-0.36%
H:
0.0%
C:
0.0%
LLY
|
News
|
$732.2
-1.81%
0.18%
2.1M
|
Health Technology
|
143.47%
|
O:
-0.77%
H:
0.99%
C:
0.49%
ALB
|
News
|
$115.27
0.93%
-0.23%
2.2M
|
Process Industries
|
-44.04%
|
O:
1.31%
H:
2.06%
C:
-1.76%
ABBV
|
News
|
$167.8
-1.03%
-0.06%
4.1M
|
Health Technology
|
-1.2%
|
O:
-0.31%
H:
0.74%
C:
-1.18%
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
-18.03%
|
O:
-3.25%
H:
0.0%
C:
0.0%
AZN
|
News
|
$71.175
0.46%
0.46%
6.1M
|
Health Technology
|
0.81%
|
O:
-2.32%
H:
0.43%
C:
-0.55%
report
approval
growth
market
drug
ViiV Healthcare Announces US FDA Approval of Cabenuva (cabotegravir, rilpivirine) for Virologically Suppressed Adolescents Living With HIV Who Are 12 Years of Age or Older and Weigh at Least 35 kg
Published:
2022-03-29
(Crawled : 18:00)
- biospace.com/
GLAXF
|
News
|
$19.54
-14.18%
2.6K
|
Health Technology
|
-7.5%
|
O:
-0.28%
H:
0.0%
C:
-1.87%
PFE
|
News
4
|
$26.27
-0.19%
-0.15%
23M
|
Health Technology
|
-50.69%
|
O:
1.35%
H:
0.15%
C:
-2.33%
JNJ
|
News
|
$148.53
-0.69%
-0.14%
9.6M
|
Health Technology
|
-16.12%
|
O:
1.05%
H:
0.0%
C:
0.0%
GSK
|
News
|
$40.86
-0.92%
-0.15%
1.7M
|
Health Technology
|
-5.87%
|
O:
1.17%
H:
0.0%
C:
0.0%
fda
approval
hiv
order
ViiV Healthcare Announces US FDA Approval of Cabenuva (cabotegravir, rilpivirine) for Use Every Two Months, Expanding the Label of the First and Only Complete Long-Acting HIV Treatment
Published:
2022-02-01
(Crawled : 14:30)
- biospace.com/
PFE
|
News
4
|
$26.27
-0.19%
-0.15%
23M
|
Health Technology
|
-50.14%
|
O:
0.09%
H:
0.8%
C:
0.63%
JNJ
|
News
|
$148.53
-0.69%
-0.14%
9.6M
|
Health Technology
|
-13.56%
|
O:
0.22%
H:
0.0%
C:
0.0%
GSK
|
News
|
$40.86
-0.92%
-0.15%
1.7M
|
Health Technology
|
-8.79%
|
O:
0.45%
H:
0.53%
C:
0.42%
treatment
fda
health
fda approval
thc
approval
hiv
GSK receives FDA accelerated approval for JEMPERLI (dostarlimab-gxly) for adult patients with mismatch repair-deficient (dMMR) recurrent or advanced solid tumors
Published:
2021-08-17
(Crawled : 21:00)
- prnewswire.com
GSK
|
News
|
$40.86
-0.92%
-0.15%
1.7M
|
Health Technology
|
-3.47%
|
O:
0.17%
H:
0.66%
C:
-0.59%
fda
solid tumors
approval
dostarlimab
FDA grants accelerated approval for GSK's JEMPERLI (dostarlimab-gxly) for women with recurrent or advanced dMMR endometrial cancer
Published:
2021-04-22
(Crawled : 21:00)
- biospace.com/
GSK
|
News
|
$40.86
-0.92%
-0.15%
1.7M
|
Health Technology
|
6.82%
|
O:
-1.15%
H:
0.36%
C:
-0.34%
fda
women
cancer
trial
approval
granted
grant
dostarlimab
Gainers vs Losers
62%
38%
Top 10 Gainers
CSSE
4
|
$0.4323
183.85%
64.77%
220M
|
Consumer Services
BOF
|
$1.99
70.09%
41.21%
110M
|
ILAG
|
$0.51
6.03%
40.62%
1.7M
|
LICN
|
$0.941
68.04%
40.49%
15M
|
AMST
|
$3.31
65.5%
39.58%
70M
|
Technology Services
MTC
|
$3.615
61.38%
38.04%
9.3M
|
Technology Services
WIMI
|
$1.15
58.53%
36.92%
19M
|
Technology Services
AIH
|
$0.45
12.5%
30.92%
320K
|
Health Services
MULN
|
News
|
$3.78
38.46%
27.78%
13M
|
Information
RILY
|
$29.86
37.48%
27.26%
12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.